Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils

The Journal of Antimicrobial Chemotherapy
H Pruul, P J McDonald

Abstract

The post-antibiotic effect (PAE) of lomefloxacin against Escherichia coli and Pseudomonas aeruginosa was determined and compared with various other antibiotics. All the quinolones tested, and chloramphenicol and gentamicin, possessed PAE activity. At 10 x MIC and 30 min exposure, the PAEs against E. coli were 1.6, 1.3, and 1.8 h for lomefloxacin, ciprofloxacin and norfloxacin respectively, and for P. aeruginosa the equivalent PAEs were 1.1, 1 and 0.5 h. The lomefloxacin PAE was dose-dependent and exposure for 5 min was sufficient to give optimal PAE at high concentrations of lomefloxacin. Such brief exposure rapidly blocked bacterial nucleic acid biosynthesis. Lomefloxacin pretreated bacteria were more susceptible to killing by PMN than untreated bacteria. Optimum enhancement of phagocytic killing of E. coli occurred when exposure to lomefloxacin was associated with an 80% decrease in cfu during pretreatment. Maximum PMN activity against P. aeruginosa occurred when bacteria were exposed to lomefloxacin producing change in cfu of +0.2 log10 to -0.7 log10. These results indicate that phenotypic changes of P. aeruginosa and E. coli exposed to lomefloxacin render the bacteria more susceptible to phagocytic killing.

Citations

May 1, 1993·Diagnostic Microbiology and Infectious Disease·S A Sonstein, J C Burnham
Dec 1, 1992·International Journal of Antimicrobial Agents·E Rizk
Sep 28, 2001·International Journal of Antimicrobial Agents·F Van Bambeke, P M Tulkens
Jul 13, 2004·The New England Journal of Medicine·Sheila A LukehartJeffrey D Klausner
Apr 6, 1999·APMIS. Supplementum·K Fuursted
Oct 19, 2000·Antimicrobial Agents and Chemotherapy·A NovelliT Mazzei
Apr 6, 1992·The American Journal of Medicine·K H Mayer, J A Ellal
Mar 10, 2001·Journal of Chemotherapy·S ScelziM Rizzo
Jun 5, 2003·Sexually Transmitted Diseases·John M Blandford, Thomas L Gift
Mar 27, 2002·Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine·S NazifiS M Ghavami
Aug 1, 1996·Antimicrobial Agents and Chemotherapy·H Pruul, P J McDonald

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.